Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by γIFN treatment

Tissue Antigens

Volumn 56, Issue 1, 2000, Pages 30-37

  Frumento, G ^a   Franchello, S ^a   Palmisano, G L ^a   Nicotra, M R ^b,c   Giacomini, P ^b   Loke, Y W ^d   Geraghty, D E ^e   Maio, M ^f   Manzo, C ^g   Natali, P G ^b   Ferrara, G B ^a,h,i  

^a UNIVERSITY OF GENOA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e Fred Hutchinson Cancer Research Center   (United States)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

HLA G; Interferon; Melanoma; Nevus

Indexed keywords

GAMMA INTERFERON; HLA G ANTIGEN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MELANOMA; MELANOMA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; INTERFERON TYPE II; MELANOMA; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0033924911     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2000.560104.x     Document Type: Article

References (24)

1. 1. Carosella ED, Dausset J, Kirszembaum M. HLA-G revised. Immunol Today 1996: 17: 407-9.
2. 2. Le Bouteiller P. HLA-G: on the track of immunological functions. Eur J Immunogenet 1997: 24: 397-408.
3. 3. Lee N, Malacko AR, Ishitani A et al. The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity 1995: 3: 591-600.
4. 4. Mandelboim O, Pazmany L, Davis DM et al. Multiple receptors for HLA-G on human natural killer cells. Proc Natl Acad Sci U S A 1997: 94: 14666-70.
5. 5. Soderstrom K, Corliss B, Lanier L, Phillips J. CD94/NKG2 is the predominant inhibitory receptor involved in recognition of HLA-G by decidual and peripheral blood NK cells. J Immunol 1997: 159: 1072-6.
6. 6. Loke YW, King A, Burrows T et al. Evaluation of trophoblast HLA-G antigen with a specific monoclonal antibody. Tissue Antigens 1997: 50: 135-46.
7. 7. Blaschitz A, Lenfant F, Mallet V et al. Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur J Immunol 1997: 27: 3380-8.
8. 8. Rouass-Freiss N, Marchal-Bras Goncalves R, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A 1997: 94: 11520-5.
9. 9. Chumbley G, King A, Robertson K, Holmes N, Loke YW. Resistance of HLA-G and HLA-A2 transfectants to lysis by decidual NK cells. Cell Immunol 1994: 155: 312-22.
10. 10. Pazmany L, Mandelboim O, Vales-Gomez M, Davis DM, Reyburn HT, Strominger JL. Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. Science 1996: 274: 792-5.
11. 11. Rouas-Freiss N, Marchal RE, Kirszembaum M, Dausset J, Carosella ED. The α1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells. Is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci U S A 1997: 94: 5249-54.
12. 12. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 1997: 18: 89-95.
13. 13. Amiot L, Onno M, Renard I, Drenou B, Guillaudeux T, Le Bouteiller P, Fauchet R. HLA-G transcription studies during the different stages of normal and malignant hematopoiesis. Tissue Antigens 1996: 47: 408-13.
14. 14. Paul P, Rouass-Freiss N, Khalil-Daher I et al. HLA-G expression in melanoma: a way for rumor cells to escape from immunosurveilllance. Proc Natl Acad Sci U S A 1998: 95: 4510-5.
15. 15. Yang Y, Chu W, Geraghty DE, Hunt JS. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-γ. J Immunol 1996: 156: 4224-31.
16. 16. Amiot L, Onno M, Drenou B, Monvoisin C, Fauchet R. HLA-G class I gene expression in normal and malignant hematopoietic cells. Hum Immunol 1998: 59: 524-8.
17. 17. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Kian Ang K. Cutaneous melanoma. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th edition. Philadelpia: Lippincott-Raven, 1997: 1947-94.
18. 18. Carrel S, Tosi R, Gross N, Tanigaky N, Carmagnola L, Accolla R. Subsets of human Ia-like molecules defined by monoclonal antibodies. Mol Immunol 1981: 18: 403-11.
19. 19. Ziegler A, Gotz H, Heinig J et al. Analysis of sequential immunoprecipitations of the specificities of the monoclonal antibodies Tu22, Tu34,Tu35, Tu36, Tu37, Tu39, Tu43, Tu58 and Yd1/63:Hlk directed against human HLA class II antigens. Immunobiology 1986: 171: 77-92.
20. 20. Giacomini P, Giorda E, Fraioli R et al. Low prevalence of selective HLA-A and -B epitope losses in early-passage tumor cell lines. Cancer Res 1999: 59: 2657-67.
21. 21. Lopez-Botet M, Navarro F, Llano M. How do NK cells sense the expression of HLA-G class Ib Molecules? Sem Canc Biol 1999: 9: 19-26.
22. 22. Real LM, Cabrera T, Collado A et al. Expression of HLA-G in human tumors is not a frequent event. Int J Cancer 1999: 81: 512-8.
23. 23. Paul P, Cabestré FA, Le Gal FA et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 1999: 59: 1954-60.
24. 24. Pangault C, Amiot L, Caulet-Maugendre ? et al. HLA-G protein expression is not induced during malignant transformation. Tissue Antigens 1999: 53: 335-45.